Metyrapone, an inhibitor of corticosteroid biosynthesis, is used in the diagnosis and treatment of adrenocortical hyperfunction. The authors describe the excretion of metyrapone and its metabolite, rac-metyrapol, in milk from a lactating woman requiring metyrapone treatment (250 mg 4 times daily). At steady state, the average concentrations in milk and absolute and relative infant doses were 11 µg/L, 1.7 µg/kg/d, and 0.02%, respectively, for metyrapone, and 48.5 µg/L, 7.3 µg/kg/d, and 0.08%, respectively, for rac- metyrapol. The findings suggest that maternal metyrapone use during breastfeeding is extremely unlikely to be a significant risk for the breastfed infant. J Hum Lact. 25(4):451-454.
Chiarotto JA, Wainer IWDetermination of metyrapone and the enantiomers of its chiral metabolite metyrapol in human plasma and urine using coupled achiral-chiral liquid chromatography . J Chromatogr B Biomed Appl. 1995;665:147-154.
3.
Combourieu B. , Besse P., Sancelme M., Maser E., Delort AMEvidence of metyrapone reduction by two Mycobacterium strains shown by 1H NMR. Biodegradation. 2004 ;15:125-132.
4.
Begg EJ, Duffull SB, Hackett LP, Ilett KFStudying drugs in human milk: time to unify the approach. J Hum Lact. 2002;18: 319-328.
5.
Thomann P.Non-compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, eds. TopFit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart : Gustav Fischer; 1993:5-66.
6.
Bennett PNUse of the monographs on drugs. In: Bennett PN, ed. Drugs and Human Lactation. 2nd ed. Amsterdam: Elsevier; 1996:67-74.
7.
BNF for Children.London: BMJ Publishing Group; 2006.
